Molecular MRD is strongly prognostic in patients with <i>NPM1</i>-mutated AML receiving venetoclax-based nonintensive therapy
Jad Othman(The University of Sydney), Richard Dillon(King's College London), Sun Loo(Northern Health), Andrew H. Wei(The Royal Melbourne Hospital), Joe W. Cross, Pramila Krishnamurthy(King's College London), Adam Ivey(The Alfred Hospital), Johnathon Elliot(The Christie Hospital), Paolo Gallipoli(Wellcome/MRC Cambridge Stem Cell Institute), Jenny O’Nions(University College London Hospitals NHS Foundation Trust), Pallavi Kalkur(Southend Hospital), Ing Soo Tiong(The University of Melbourne), Scott Marshall(South Tyneside and Sunderland NHS Foundation Trust), Katya Mokretar, Francesca Hogan(University Hospital of Wales), Rob S. Sellar(University College London), Nigel H. Russell(Guy's and St Thomas' NHS Foundation Trust), Mike Dennis(The Christie NHS Foundation Trust), Chun Yew Fong(Olivia Newton-John Cancer Wellness & Research Centre), Anjum Khan(Leeds Teaching Hospitals NHS Trust), Priyanka Mehta, Sateesh Nagumantry(Peterborough City Hospital), Mariam Amer(University Hospital Southampton NHS Foundation Trust), Srinivas Pillai(University Hospitals of North Midlands NHS Trust), Wei Yee Chan(Royal London Hospital), Francesca Crolla(Musgrove Park Hospital), John Laurie(Worthing Hospital), Vidhya Murthy(NIHR Surgical Reconstruction and Microbiology Research Centre), Nicola Potter(European Bioinformatics Institute), Thomas Taylor(Nottingham University Hospitals NHS Trust), Sofia Galli(Frimley Park Hospital), Rui Zhao(Torbay Hospital), Anne‐Louise Latif(Queen Elizabeth University Hospital), Charles Crawley(Addenbrooke's Hospital), Michael J. Austin(Queen Mary University of London)
Cited by 65
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k